OCEA · Ocean Biomedical, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $18.0K | - | - | - | $26.0K | - | $1.86M | $3.19M | $393.0K | - |
| SG&A | $940.0K | - | $768.0K | $682.0K | $569.0K | - | $1.31M | $2.65M | $4.83M | - |
| Total Operating Expenses | $958.0K | - | $768.0K | $682.0K | $595.0K | - | $2.65M | $6.90M | $5.22M | - |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | ($958.0K) | - | ($768.0K) | ($682.0K) | ($595.0K) | - | ($2.65M) | ($2.68M) | ($5.22M) | - |
| Interest Expense | $637.0K | - | - | - | - | - | $0 | $24.0K | $883.5K | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($8.24M) | - | ($5.53M) | ($17.23M) | $13.00M | - | ($14.09M) | ($13.03M) | ($67.40M) | - |
| EPS - Basic | ($0.09) | - | ($0.20) | ($0.63) | $0.48 | - | ($0.16) | ($0.31) | ($0.23) | - |
| EPS - Diluted | ($0.09) | - | ($0.20) | ($0.63) | $0.48 | - | ($0.53) | ($0.49) | ($2.90) | - |
Balance Sheet
| Line item | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $800.0K | $200.0K | $200.0K | $200.0K | $19.0K | $1.00M | $1.00M | $1.16M | $306.0K | $328.3K |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $16.39M | $15.90M | $16.57M | $17.18M | $16.88M | $16.18M | $16.05M | $14.04M | $15.44M | $324.8K |
| Current Assets | $1.49M | $812.0K | $1.04M | $1.28M | $1.80M | $2.11M | $1.03M | $2.16M | $306.0K | $468.0K |
| Total Assets | $1.58M | $902.0K | $1.13M | $1.85M | $2.95M | $5.50M | $1.03M | $20.92M | $24.98M | $110.91M |
| Current Liabilities | $26.57M | $33.89M | $33.65M | $30.74M | $30.11M | $30.01M | $30.85M | $26.68M | $23.43M | $3.46M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $93.98M | $98.52M | $99.22M | $94.59M | $78.73M | $96.26M | $76.25M | $29.32M | $55.06M | $6.61M |
| Stockholders' Equity | ($92.40M) | ($97.62M) | ($98.08M) | ($92.74M) | ($75.78M) | ($90.76M) | ($75.22M) | ($8.40M) | $1.54M | ($6.15M) |
| Retained Earnings | ($213.78M) | ($205.53M) | ($205.82M) | ($200.29M) | ($183.06M) | ($196.06M) | ($179.20M) | ($162.02M) | ($148.99M) | ($2.77M) |
Cash Flow
| Line item | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($356.0K) | - | - | - | ($485.0K) | - | - | - | ($2.65M) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | $909.0K | - | - | - | - | - | - | - | $2.92M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -520.9% | - | -488.3% | -931.1% | 441.2% | - | -1366.3% | -62.3% | -269.8% | - |
| Return on equity | 8.9% | - | 5.6% | 18.6% | -17.2% | - | 18.7% | 155.1% | -4365.3% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.06 | 0.02 | 0.03 | 0.04 | 0.06 | 0.07 | 0.03 | 0.08 | 0.01 | 0.14 |
| Quick ratio | 0.06 | 0.02 | 0.03 | 0.04 | 0.06 | 0.07 | 0.03 | 0.08 | 0.01 | 0.14 |
| Cash ratio | 0.03 | 0.01 | 0.01 | 0.01 | 0.00 | 0.03 | 0.03 | 0.04 | 0.01 | 0.09 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -1.5x | - | - | - | - | - | - | -111.5x | -5.9x | - |
| Equity multiplier | -0.02 | -0.01 | -0.01 | -0.02 | -0.04 | -0.06 | -0.01 | -2.49 | 16.18 | -18.05 |
| Liabilities / Assets | 59.41 | 109.22 | 87.65 | 51.10 | 26.72 | 17.50 | 73.96 | 1.40 | 2.20 | 0.06 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -61.0% | - | 71.1% | 74.6% | 88.6% | - | -93.9% | -724.0% | -2925.6% | - |
| Net income growth (YoY) | - | - | 60.8% | -32.3% | - | - | -1284.0% | -6944.7% | -40573.3% | - |
| EPS growth (YoY) | - | - | 62.3% | -28.6% | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -21.9% | -7.6% | -30.4% | -1004.0% | - | -1376.8% | -1520.7% | -282.8% | - | -233.3% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Ocean Biomedical against the 5 most active filers in the same SIC group.